Puma Biotechnology to Host Conference Call to Discuss Second Quarter 2024 Financial Results
Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
Puma Biotechnology Announces Presentation of Findings from a Phase I/Ib Study of Alisertib in Advanced EGFR-Mutated Lung Cancer
Puma Biotechnology Announces Presentation of Findings from a Phase II Study of Alisertib in Endocrine-Resistant Metastatic Breast Cancer (TBCRC 041)
Puma Biotechnology to Join Russell 3000 Index
Puma Biotechnology Announces Publication of Alisertib Abstract Titles for the 2024 ASCO Annual Meeting
Pfizer wins $107.5M from AZ in US cancer drug patent trial
Puma Biotechnology Reports First Quarter Financial Results
Puma Biotechnology to Host Conference Call to Discuss First Quarter 2024 Financial Results